Literature DB >> 16777521

Shortening of the ventricular fibrillatory intervals after administration of verapamil in a patient with Brugada syndrome and vasospastic angina.

Masaomi Chinushi1, Minoru Tagawa, Yuichi Nakamura, Yoshifusa Aizawa.   

Abstract

A 43-year-old man presented with electrocardiographic findings consistent with Brugada syndrome. Though the baseline coronary angiogram was normal, intracoronary infusion of ergonovine maleate caused complete occlusion of the left anterior descending and a 99% occlusion of the proximal right coronary artery, each relieved by intracoronary isosorbide dinitrate. Double extrastimuli delivered at the right ventricular outflow tract induced ventricular fibrillation terminated by a 200-J shock. Verapamil, 10 mg IV, increased ST-segment elevation and programmed stimulation repeated after the drug induced ventricular fibrillation with shorter F-F intervals and lower amplitude signals, which was not terminated by 200 J and required an additional 360-J shock. Ca2+ antagonism may have been adverse in this patient with Brugada syndrome because the drug has the potential to increase the voltage gradient through the right ventricle and to slow intraventricular conduction at very fast heart rates.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16777521     DOI: 10.1016/j.jelectrocard.2005.10.002

Source DB:  PubMed          Journal:  J Electrocardiol        ISSN: 0022-0736            Impact factor:   1.438


  2 in total

1.  A case of Brugada syndrome coexisting with vasospastic angina: Caution should be taken when using calcium channel blockers.

Authors:  Takahisa Yoshikawa; Chisato Izumi; Kazuaki Kaitani; Yoshihisa Nakagawa
Journal:  J Cardiol Cases       Date:  2011-10-02

Review 2.  Drugs and Brugada syndrome patients: review of the literature, recommendations, and an up-to-date website (www.brugadadrugs.org).

Authors:  Pieter G Postema; Christian Wolpert; Ahmad S Amin; Vincent Probst; Martin Borggrefe; Dan M Roden; Silvia G Priori; Hanno L Tan; Masayasu Hiraoka; Josep Brugada; Arthur A M Wilde
Journal:  Heart Rhythm       Date:  2009-07-08       Impact factor: 6.343

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.